584 related articles for article (PubMed ID: 24782985)
41. Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy.
Catanzaro E; Feron O; Skirtach AG; Krysko DV
Front Immunol; 2022; 13():925290. PubMed ID: 35844506
[TBL] [Abstract][Full Text] [Related]
42. Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.
Bastin D; Walsh SR; Al Saigh M; Wan Y
Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536388
[TBL] [Abstract][Full Text] [Related]
43. Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer.
Kim R; Kin T
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638242
[TBL] [Abstract][Full Text] [Related]
44. Evolution of oncolytic viruses: novel strategies for cancer treatment.
Atherton MJ; Lichty BD
Immunotherapy; 2013 Nov; 5(11):1191-206. PubMed ID: 24188674
[TBL] [Abstract][Full Text] [Related]
45. Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses.
Zhang B; Wang X; Cheng P
Front Oncol; 2020; 10():561372. PubMed ID: 33680911
[TBL] [Abstract][Full Text] [Related]
46. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I; Sprooten J; De Ruysscher D; Tejpar S; Vandenberghe P; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L; Garg AD
Oncoimmunology; 2020; 9(1):1703449. PubMed ID: 32002302
[TBL] [Abstract][Full Text] [Related]
47. The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy.
Deng W; Shang H; Tong Y; Liu X; Huang Q; He Y; Wu J; Ba X; Chen Z; Chen Y; Tang K
J Nanobiotechnology; 2024 Mar; 22(1):97. PubMed ID: 38454419
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
49. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy.
Jiang H; Fueyo J
Oncoimmunology; 2014; 3(7):e947872. PubMed ID: 25954598
[TBL] [Abstract][Full Text] [Related]
50. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
[TBL] [Abstract][Full Text] [Related]
51. Cell death induced by cytotoxic CD8
Jaime-Sanchez P; Uranga-Murillo I; Aguilo N; Khouili SC; Arias MA; Sancho D; Pardo J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32241808
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.
Calvillo-Rodríguez KM; Lorenzo-Anota HY; Rodríguez-Padilla C; Martínez-Torres AC; Scott-Algara D
Front Immunol; 2023; 14():1294434. PubMed ID: 38077402
[TBL] [Abstract][Full Text] [Related]
53. Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity.
Li Y; Guo Y; Zhang K; Zhu R; Chen X; Zhang Z; Yang W
Adv Sci (Weinh); 2024 Jan; 11(3):e2306580. PubMed ID: 37984863
[TBL] [Abstract][Full Text] [Related]
54. The inducers of immunogenic cell death for tumor immunotherapy.
Li X
Tumori; 2018; 104(1):1-8. PubMed ID: 28967094
[TBL] [Abstract][Full Text] [Related]
55. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
56. Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy.
Gupta G; Borglum K; Chen H
J Cancer Immunol (Wilmington); 2021; 3(1):47-59. PubMed ID: 34263254
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
58. Recent advances in targeting cancer stem cells using oncolytic viruses.
Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
[TBL] [Abstract][Full Text] [Related]
59. Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.
Yin J; Markert JM; Leavenworth JW
Front Oncol; 2017; 7():136. PubMed ID: 28695111
[TBL] [Abstract][Full Text] [Related]
60. Nanotechnology-Assisted Immunogenic Cell Death for Effective Cancer Immunotherapy.
Guo Y; Ma R; Zhang M; Cao Y; Zhang Z; Yang W
Vaccines (Basel); 2023 Aug; 11(9):. PubMed ID: 37766117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
